Esthesioneuroblastoma: An Update on the Massachusetts Eye and Ear Infirmary and Massachusetts General Hospital Experience with Craniofacial Resection, Proton Beam Radiation, and Chemotherapy

Abstract

Objectives To update the Massachusetts General Hospital (MGH) and Massachusetts Eye and Ear Infirmary (MEEI) experience in the management of esthesioneuroblastoma (ENB) with multimodality therapy and to reassess treatment outcomes and complications in a larger cohort with longer follow-up times.

Design A retrospective chart review.

Setting A tertiary referral center.

Participants All patients presenting with ENB and managed at the MGH and MEEI from 1997 to 2013.

Main Outcome Measures Disease-free and overall survival.

Results Twenty-two patients were identified with an average follow-up of 73 months. Ten patients presented with Kadish stage B disease and 12 with stage C disease. A total of six patients (27%) developed regional metastases. Treatment for all patients included craniofacial resection (CFR) followed by proton beam irradiation with or without chemotherapy. The 5-year disease-free and overall survival rates were 86.4% and 95.2%, respectively, by Kaplan-Meier analysis. Negative margins were a significant factor in disease-free survival. One patient experienced severe late-radiation toxicity.

Conclusions ENB is safely and effectively treated with CFR followed by proton beam irradiation. The high incidence of regional metastases warrants strong consideration for elective neck irradiation. Proton beam radiation is associated with lower rates of severe late-radiation toxicity than conventional radiotherapy.

Keywords

esthesioneuroblastoma - craniofacial resection - proton beam radiation - sinonasal malignancy

• References

• 1 Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol 2001; 2 (11) 683-690
• 2 Bhattacharyya N, Thornton AF, Joseph MP, Goodman ML, Amrein PC. Successful treatment of esthesioneuroblastoma and neuroendocrine carcinoma with combined chemotherapy and proton radiation. Results in 9 cases. Arch Otolaryngol Head Neck Surg 1997; 123 (1) 34-40
• 3 Bailey BJ, Barton S. Olfactory neuroblastoma. Management and prognosis. Arch Otolaryngol 1975; 101 (1) 1-5
• 4 Beitler JJ, Fass DE, Brenner HA , et al. Esthesioneuroblastoma: is there a role for elective neck treatment?. Head Neck 1991; 13 (4) 321-326
• 5 Rinaldo A, Ferlito A, Shaha AR, Wei WI, Lund VJ. Esthesioneuroblastoma and cervical lymph node metastases: clinical and therapeutic implications. Acta Otolaryngol 2002; 122 (2) 215-221
• 6 Berger L, Luc R, Richard D. L'esthésioneuroépithéliome olfactif. Bull Assoc Fr Etud Cancer 1924; 13: 410-421
• 7 Levine PA, Gallagher R, Cantrell RW. Esthesioneuroblastoma: reflections of a 21-year experience. Laryngoscope 1999; 109 (10) 1539-1543
• 8 Loy AH, Reibel JF, Read PW , et al. Esthesioneuroblastoma: continued follow-up of a single institution's experience. Arch Otolaryngol Head Neck Surg 2006; 132 (2) 134-138
• 9 Nishimura H, Ogino T, Kawashima M , et al. Proton-beam therapy for olfactory neuroblastoma. Int J Radiat Oncol Biol Phys 2007; 68 (3) 758-762
• 10 Simon JH, Zhen W, McCulloch TM , et al. Esthesioneuroblastoma: the University of Iowa experience 1978–1998. Laryngoscope 2001; 111 (3) 488-493
• 11 Dias FL, Sa GM, Lima RA , et al. Patterns of failure and outcome in esthesioneuroblastoma. Arch Otolaryngol Head Neck Surg 2003; 129 (11) 1186-1192
• 12 Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970–1990. Laryngoscope 1992; 102 (8) 843-849
• 13 Constantinidis J, Steinhart H, Koch M , et al. Olfactory neuroblastoma: the University of Erlangen-Nuremberg experience 1975–2000. Otolaryngol Head Neck Surg 2004; 130 (5) 567-574
• 14 Resto VA, Eisele DW, Forastiere A, Zahurak M, Lee DJ, Westra WH. Esthesioneuroblastoma: the Johns Hopkins experience. Head Neck 2000; 22 (6) 550-558
• 15 Nichols AC, Chan AW, Curry WT, Barker FG, Deschler DG, Lin DT. Esthesioneuroblastoma: the Massachusetts Eye and Ear Infirmary and Massachusetts General Hospital experience with craniofacial resection, proton beam radiation, and chemotherapy. Skull Base 2008; 18 (5) 327-337
• 16 Kadish S, Goodman M, Wang CC. Olfactory neuroblastoma. A clinical analysis of 17 cases. Cancer 1976; 37 (3) 1571-1576
• 17 Lund VJ, Howard D, Wei W, Spittle M. Olfactory neuroblastoma: past, present, and future?. Laryngoscope 2003; 113 (3) 502-507
• 18 Argiris A, Dutra J, Tseke P, Haines K. Esthesioneuroblastoma: the Northwestern University experience. Laryngoscope 2003; 113 (1) 155-160
• 19 Koka VN, Julieron M, Bourhis J , et al. Aesthesioneuroblastoma. J Laryngol Otol 1998; 112 (7) 628-633
• 20 Irish J, Dasgupta R, Freeman J , et al. Outcome and analysis of the surgical management of esthesioneuroblastoma. J Otolaryngol 1997; 26 (1) 1-7
• 21 Morita A, Ebersold MJ, Olsen KD, Foote RL, Lewis JE, Quast LM. Esthesioneuroblastoma: prognosis and management. Neurosurgery 1993; 32 (5) 706-714 ; discussion 714–715
• 22 Shaari CM, Catalano PJ, Sen C, Post K. Central nervous system metastases from esthesioneuroblastoma. Otolaryngol Head Neck Surg 1996; 114 (6) 808-812
• 23 Hwang SK, Paek SH, Kim DG, Jeon YK, Chi JG, Jung HW. Olfactory neuroblastomas: survival rate and prognostic factor. J Neurooncol 2002; 59 (3) 217-226
• 24 Chan AW, Liebsch NJ. Proton radiation therapy for head and neck cancer. J Surg Oncol 2008; 97 (8) 697-700
• 25 van de Water TA, Bijl HP, Schilstra C, Pijls-Johannesma M, Langendijk JA. The potential benefit of radiotherapy with protons in head and neck cancer with respect to normal tissue sparing: a systematic review of literature. Oncologist 2011; 16 (3) 366-377
• 26 Fitzek MM, Thornton AF, Varvares M , et al. Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy. Cancer 2002; 94 (10) 2623-2634
• 27 Pommier P, Liebsch NJ, Deschler DG , et al. Proton beam radiation therapy for skull base adenoid cystic carcinoma. Arch Otolaryngol Head Neck Surg 2006; 132 (11) 1242-1249